Can calprotectin levels be normal in a patient with inflammatory bowel disease (IBD)?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: January 7, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Ask Question

Can Calprotectin Be Normal in IBD?

Yes, calprotectin can be normal in patients with inflammatory bowel disease, particularly in those with true clinical remission, but also in a significant minority of patients with active endoscopic inflammation—creating a false-negative scenario that requires careful clinical interpretation.

Understanding False-Negative Calprotectin Results

Patients in True Remission

  • Calprotectin levels <50 μg/g reliably indicate absence of active inflammation in patients with IBD who are in symptomatic remission, with a sensitivity of 90.6% for detecting endoscopically active disease 1
  • In asymptomatic UC patients on stable maintenance therapy, approximately 15% still have moderate to severe endoscopic inflammation despite being symptom-free 2
  • Calprotectin <150 μg/g suggests minimal inflammation and can reliably rule out active inflammation in patients in symptomatic remission 3

False-Negative Rates in Symptomatic Patients

  • In Crohn's disease patients with moderate to severe symptoms (PRO2 >13 or PRO3 >21): Normal calprotectin (<150 μg/g) has a false-negative rate of 26.4%, meaning over one-quarter of symptomatic patients with normal calprotectin actually have endoscopic activity 4
  • In Crohn's disease patients with mild symptoms: The false-negative rate is even higher at 24.7% when calprotectin is <150 μg/g 4
  • In UC patients with mild symptoms (infrequent rectal bleeding and/or increased stool frequency): Approximately 50% have moderate to severe endoscopic inflammation, yet some will have normal or low calprotectin 2

Clinical Scenarios Where Normal Calprotectin Occurs Despite Active IBD

Isolated Small Bowel Disease

  • Calprotectin may be falsely normal in patients with predominantly small bowel Crohn's disease, as the marker is less sensitive for proximal disease 3
  • For these patients, complementing calprotectin with other monitoring methods (such as cross-sectional imaging) is recommended 3

Coexisting IBS-Like Symptoms

  • IBD patients in remission who have coexisting IBS-like symptoms (fulfilling Rome II criteria in 24.6% of UC and 21.4% of CD patients) can have normal calprotectin despite symptoms 5
  • This underscores calprotectin's utility in distinguishing true inflammatory flares from functional symptoms 5, 6

Guideline-Based Management Approach

When Calprotectin is Normal but Symptoms Persist

For patients with mild symptoms and normal biomarkers (calprotectin <150 μg/g, CRP <5 mg/L):

  • The AGA recommends endoscopic assessment of disease activity rather than empiric treatment adjustment 4
  • This is critical because a significant proportion of symptomatic patients with normal calprotectin may have endoscopic activity and would be incorrectly classified as being in remission 4

For patients with moderate to severe symptoms and normal biomarkers:

  • The AGA suggests endoscopic assessment of disease activity rather than empiric treatment adjustment, given the 26.4% false-negative rate 4
  • Do not assume symptoms are functional without endoscopic confirmation 4

Optimal Cutoff Values for Different Clinical Contexts

For ruling out inflammation (high negative predictive value):

  • Use calprotectin <50 μg/g in asymptomatic patients or those recently achieving remission 2, 1
  • At this threshold, sensitivity is 92% but specificity is only 60% 1, 7

For confirming inflammation (high positive predictive value):

  • Use calprotectin >250 μg/g, which provides specificity of 82% but sensitivity drops to 80% 1
  • At 100 μg/g, sensitivity is 84% with specificity of 66% 1

Common Pitfalls to Avoid

Don't Rely Solely on Calprotectin in Symptomatic Patients

  • Never dismiss symptoms in a patient with normal calprotectin without considering endoscopic evaluation, especially in Crohn's disease where false-negative rates exceed 24% 4
  • Symptoms alone are inadequate for monitoring, but normal biomarkers don't exclude active disease 3

Technical Factors Affecting Results

  • Variability exists between different assays, between stool samples from the same patient during one day, and related to interval between stools 1
  • Use the first stool passed in the morning and store for no more than 3 days at room temperature before analysis 1

Consider Alternative Diagnoses

  • Normal calprotectin in a symptomatic IBD patient may indicate coexisting IBS, medication side effects, bile acid malabsorption (especially post-ileocecal resection), or stricturing disease without active inflammation 5, 6

Monitoring Strategy for Patients with Normal Calprotectin

  • For patients in symptomatic remission with calprotectin <150 μg/g, no intervention is needed but continue monitoring every 3-6 months 8, 3
  • For stable disease with consistent symptomatic remission, test calprotectin every 6-12 months 3
  • If discordance exists between symptoms and biomarkers, repeat measurement in 3-6 months before proceeding to endoscopy 3

References

3
Guideline

Fecal Calprotectin Monitoring in Inflammatory Bowel Disease

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

8
Guideline

Treatment for Elevated Fecal Calprotectin Levels

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Related Questions

Why is my calprotectin level elevated despite negative tests for Inflammatory Bowel Disease (IBD) and absence of infectious pathogens?
What is the role of calprotectin in assessing intestinal inflammation, particularly in distinguishing between inflammatory bowel disease (IBD) and irritable bowel syndrome (IBS)?
What is the appropriate management for a patient with elevated calprotectin (fecal calprotectin) levels in the absence of a rise in inflammatory markers, such as C-reactive protein (CRP) or erythrocyte sedimentation rate (ESR), and a history of gastrointestinal symptoms or inflammatory bowel disease (IBD)?
What is stool calprotectin, how is it measured, what are the normal and abnormal cut‑offs for adults and children, and how is it used to diagnose, differentiate, and monitor inflammatory bowel disease?
In an 89‑year‑old woman who is otherwise well but presents with bloating and excess gas and has a fecal calprotectin of 71 µg/g, what is the appropriate management?
What is the appropriate use of oxacillin (a penicillin-resistant penicillin) for a patient with a complicated urinary tract infection (UTI) and potential history of methicillin-susceptible Staphylococcus aureus (MSSA)?
What is the best management approach for a geriatric patient with moderate to severe Alzheimer's type dementia, hypertension, diabetes, cardiovascular disease, and impaired renal function?
Can dexamethasone (corticosteroid) cause insomnia in patients?
What alternative can be used for a patient experiencing insomnia due to dexamethasone (corticosteroid) therapy?
What are suitable alternatives to Farxiga (dapagliflozin) for a patient with impaired renal function and a history of cardiovascular disease?
Can a patient develop tolerance to Lamictal (lamotrigine) after years of use?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.